The Emerging Topic Conference will provide the opportunity for attendees to learn more about and improve upon their selection of precise therapy for patients with hepatocellular carcinoma. Also, attendees will increase their knowledge regarding design, implementation and participation in HCC clinical trials with an enhanced ability to assess the efficacy of treatment using a variety of response criteria.

Core Competencies:

Patient Care and Procedural Skills

Medical Knowledge

Practice-based Learning and Improvement

Systems-based Practice

Provide Patient-centered Care

Work in Interdisciplinary Teams

Roles/Responsibilities

Interprofessional Communication

Apply Quality Improvement

Teams and Teamwork

Utilize Informatics

Program Chairs: 

Josep M. Llovet, MD, PhD, FAASLD 

Lewis R. Roberts, MBChB, PhD, FAASLD

CME Hours: 9.00 AMA PRA Category 1 Credits

MOC Points: 9.00 MOC Points 

How to access your CME Certificate from the 2019 AASLD Emerging Topic Conference:

1. Click HERE and login if you are not already logged in. 

2. Complete the Course Evaluation.

3. Print the Certificate of Attendance.

4. Attest to the EACH session you attended at the conference. (You will simply click on the session you attended, attest and receive credit. Please note: the credits earned will be applied to your cohesive CME Certificate which will have all session completed credits on it.)

5. Click the View CME Certificate tab on the top of the Package. You can also access your CME Certificate at the bottom of the page. 

6. For ABIM MOC, complete the MOC evaluation and ensure your ABIM ID and birthday are in your LiverLearning® Profile.

If you have any questions regarding the CME and or MOC process, please contact education@aasld.org. If you have any technical questions, please contact online_education@aasld.org.

• Review novel strategies for biomarker based clinical trial designs and articulate new approaches including the role of tumor biopsies and circulating cell-free based assays in guiding therapeutic decision-making.
• Understand recent advances in integrated molecular classification of HCC and their application to improved treatment of HCC.
• Review recently approved molecular therapies and anticipated novel immune-based, cellular, and oncolytic virus therapies for HCC and effectively manage the common side effects of these therapies.

• Hepatologists 
• Oncologist
• Radiologist     
• Nurses
• Nurse Practitioners    
• Pharmacists
• Physician Assistants  
• Transplant Coordinators
• Surgeons        
• Fellows/Trainees        
• Government/Regulatory Representatives
• Industry

Mitesh Borad, MD

Laura Dawson, MD, FRCPC  

Frank DeRosa, MD

Anthony B. El-Khouiery, MD

Richard Finn, MD 

Peter R. Galle, MD 

Tim Greten, MD 

Riccardo Lencioni, MD 

Josep M. Llovet, MD, PhD, FAASLD

Sumithra Mandrekar, PhD

Jorge A. Marrero, MD 

Gerold Meinhardt, MD 

Timothy Meyer, MD, PhD  

Neehar Parikh, MD, MS

Maria Reig, MD 

Lorenza Rimassa, MD 

Lewis R. Roberts, MBChB, PhD, FAASLD

Riad Salem, MD

Myron E. Schwartz, MD 

Emmanuel Thomas, MD, PhD, FAASLD

Augusto Villanueva, MD, PhD 

David Wheeler, PhD

Andrew X. Zhu, MD, PhD

Disclosures

This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Emerging Topic Conference faculty and the Clinical Research Committee and Governing Board.

As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.

Faculty Disclosures

Mitesh Borad, MD
Nothing to disclose

Laura Dawson, MD, FRCPC
Scientific Consulting: Merck                                                    
Grant/Research Support: Merck

Anthony B. El-Khoueiry, MD
Scientific Consulting: Bayer, Merck, Agenus, BMS

Richard Finn, MD
Scientific Consulting: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, EliLilly, Merck, Pfizer, Novartis

Peter R. Galle, MD
Scientific Consulting: Bayer, BMS, MSD, Sirtex, Lilly, Roche, Ipsen, Eisai, AstraZeneca

Tim Greten, MD
Nothing to disclose

Riccardo Lencioni, MD
Scientific Consulting: Eisai, Astra Zeneca

Josep M. Llovet, MD, PhD, FAASLD
Scientific Consulting:  Eli Lilly, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Blueprint, Ipsen, Glycotest, Navigant, Leerink Swann LLC, Midatech Ltd, Fortress Biotech, INC, Spring Bank Pharmaceuticals, Nucleix 
Grants/Research Support: Bayer Healthcare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb, Ipsen, Blueprint, Incyte

Sumithra J. Mandrekar, PhD
Nothing to disclose

Jorge A. Marrero, MD
Scientific Consulting: Eisai, Grail, Exelis, Astra Zeneca

Gerold Meinhardt, MD
Employee: Bayer Pharmaceuticals

Timothy Meyer, MD
Scientific Consulting: Eisai, Tarveda, Ipsen

Neehar Parikh, MD, MS
Scientific Consulting: Bayer, Eisai, Bristol-Myer Squibb
Grants/Research Support: TARGET Pharmaceuticals

Maria Reig, MD
Scientific Consulting: Bayer, BMS, Ipsen, Lilly, AstraZeneca, Roche

Lorenza Rimassa, MD
Scientific Consulting: Celgene, Eisai, Gilead, Roche, Lilly, Bayer, Sirtex Medical, Italfarmaco, Sanofi, ArQule, Baxter, Ipsen, Exelixis, Amgen, Incyte, Astra-Zeneca, AbbVie

Lewis R. Roberts, MBChB, PhD, FAASLD
Grants/Research Support: Ariad Pharmaceuticals, Wako Diagnostics, Gilead Sciences, BTG, Redhil 
Scientific Consulting: Axis Medical Education, Medscape, Grail, OncLive

Riad Salem MD
Nothing to disclose

Myron E. Schwartz, MD
Scientific Consulting: Merck

Augusto Villanueva, MD, PhD
Scientific Consulting: Exact Sciences, Guidepoint, Exelixis

David Wheeler, PhD
Nothing to disclose

Andrew X. Zhu, MD, PhD
Scientific Consulting: Bayer, Merck, Lilly, Novartis, Eisai, BMS, Roche-Genentech, Exelixis

Credits Offered

Continuing Medical Education (CME): 9.00 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): 9.00 MOC Points


Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

CME Credits

Physicians and other health care professionals seeking 9.00 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Tuesday, April 23, 2019. A link to the CME and MOC evaluation will be emailed to attendees after the conference.

ABIM MOC Points

Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Tuesday, April 23, 2019. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM and ABP by the end of April 2019 for attendees who successfully complete the MOC evaluation.